Paper39348357
Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma.
Ajadee A and 7 others. PLoS One, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma. Papers, record 39348357. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39348357
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Renal Cell | Major topic |
| Kidney Neoplasms | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Humans | |
| Prognosis | |
| Survival Analysis | |
| Gene Expression Profiling | |
| Biomarkers, Tumor | |
| Protein Interaction Maps | |
| Gene Regulatory Networks | |
| Transcriptome |
Source PubMed
References172
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29159069 | Co-expression network analysis identified six hub genes in association with progression and prognosis in human clear cell renal cell carcinoma (ccRCC). | Genom Data | 2017 | https://conductscience.org/library/papers/29159069 | PubMed |
| 2 | 33015999 | TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma. | FEBS Open Bio | 2020 | https://conductscience.org/library/papers/33015999 | PubMed |
| 3 | 36310399 | The cross-talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell Renal Cell Carcinoma cells. | FEBS Lett | 2023 | https://conductscience.org/library/papers/36310399 | PubMed |
| 4 | 34884615 | Cytochrome P450 Enzymes and Drug Metabolism in Humans. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34884615 | PubMed |
| 5 | 30371825 | PubChem 2019 update: improved access to chemical data. | Nucleic Acids Res | 2019 | https://conductscience.org/library/papers/30371825 | PubMed |
| 6 | 26221251 | Screening feature genes of osteosarcoma with DNA microarray: a bioinformatic analysis. | Int J Clin Exp Med | 2015 | https://conductscience.org/library/papers/26221251 | PubMed |
| 7 | 35442707 | A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. | Sci Transl Med | 2022 | https://conductscience.org/library/papers/35442707 | PubMed |
| 8 | 32038957 | Extent and characteristics of immune infiltration in clear cell renal cell carcinoma and the prognostic value. | Transl Androl Urol | 2019 | https://conductscience.org/library/papers/32038957 | PubMed |
| 9 | 26790128 | Downregulation of WDR20 due to loss of 14q is involved in the malignant transformation of clear cell renal cell carcinoma. | Cancer Sci | 2016 | https://conductscience.org/library/papers/26790128 | PubMed |
| 10 | 35121728 | PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. | Cell Death Dis | 2022 | https://conductscience.org/library/papers/35121728 | PubMed |
| 11 | 29264942 | MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. | Epigenomics | 2018 | https://conductscience.org/library/papers/29264942 | PubMed |
| 12 | 35853872 | Single-cell multiomics analysis reveals regulatory programs in clear cell renal cell carcinoma. | Cell Discov | 2022 | https://conductscience.org/library/papers/35853872 | PubMed |
| 13 | 36176391 | A metabolic reprogramming-related prognostic risk model for clear cell renal cell carcinoma: From construction to preliminary application. | Front Oncol | 2022 | https://conductscience.org/library/papers/36176391 | PubMed |
| 14 | 37576399 | TLR4 predicts patient prognosis and immunotherapy efficacy in clear cell renal cell carcinoma. | J Cancer | 2023 | https://conductscience.org/library/papers/37576399 | PubMed |
| 15 | 19959715 | Uromodulin levels associate with a common UMOD variant and risk for incident CKD. | J Am Soc Nephrol | 2010 | https://conductscience.org/library/papers/19959715 | PubMed |
| 16 | 27713636 | Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. | Onco Targets Ther | 2016 | https://conductscience.org/library/papers/27713636 | PubMed |
| 17 | 18587261 | Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. | Urol Int | 2008 | https://conductscience.org/library/papers/18587261 | PubMed |
| 18 | 35994213 | Metadata analysis to explore hub of the hub-genes highlighting their functions, pathways and regulators for cervical cancer diagnosis and therapies. | Discov Oncol | 2022 | https://conductscience.org/library/papers/35994213 | PubMed |
| 19 | 37353178 | Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone. | Crit Rev Oncol Hematol | 2023 | https://conductscience.org/library/papers/37353178 | PubMed |
| 20 | 37893423 | Robust Identification of Differential Gene Expression Patterns from Multiple Transcriptomics Datasets for Early Diagnosis, Prognosis, and Therapies for Breast Cancer. | Medicina (Kaunas) | 2023 | https://conductscience.org/library/papers/37893423 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42886687 | Disclosing pathogenic processes of monkeypox (MPOX) and drug repurposing through host-transcriptomics analysis. | PLoS Negl Trop Dis | 2026 | https://conductscience.org/library/papers/42886687 | PubMed |
| 41839687 | Genetic underpinnings of type-2 diabetes (T2D) with colorectal cancer (CRC): In-silico discovery of common molecular signatures, pathogenetic processes and therapeutic candidates. | J Genet Eng Biotechnol | 2026 | https://conductscience.org/library/papers/41839687 | PubMed |
| 40370100 | In-silico discovery of type-2 diabetes-causing host key genes that are associated with the complexity of monkeypox and repurposing common drugs. | Brief Bioinform | 2025 | https://conductscience.org/library/papers/40370100 | PubMed |
| 40127075 | Exploring common genomic biomarkers to disclose common drugs for the treatment of colorectal cancer and hepatocellular carcinoma with type-2 diabetes through transcriptomics analysis. | PLoS One | 2025 | https://conductscience.org/library/papers/40127075 | PubMed |
| 40114841 | In silico research of coagulation- and fibrinolysis-related genes for predicting prognosis of clear cell renal cell carcinoma. | Transl Androl Urol | 2025 | https://conductscience.org/library/papers/40114841 | PubMed |
| 40025145 | Screening of common genomic biomarkers to explore common drugs for the treatment of pancreatic and kidney cancers with type-2 diabetes through bioinformatics analysis. | Sci Rep | 2025 | https://conductscience.org/library/papers/40025145 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALDH6A1 | 4329 | PubTator's text mining | https://conductscience.org/library/genes/4329 | NCBI Gene |
| ALDOB | 229 | PubTator's text mining | https://conductscience.org/library/genes/229 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| ENO2 | 2026 | PubTator's text mining | https://conductscience.org/library/genes/2026 | NCBI Gene |
| PLG | 5340 | PubTator's text mining | https://conductscience.org/library/genes/5340 | NCBI Gene |
| SERPINA5 | 5104 | PubTator's text mining | https://conductscience.org/library/genes/5104 | NCBI Gene |
| SLC12A1 | 6557 | PubTator's text mining | https://conductscience.org/library/genes/6557 | NCBI Gene |
| SLC12A3 | 6559 | PubTator's text mining | https://conductscience.org/library/genes/6559 | NCBI Gene |
| UMOD | 7369 | PubTator's text mining | https://conductscience.org/library/genes/7369 | NCBI Gene |
Data9
The data bank entries PubMed's record names. Trial numbers are under Trials.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39348357
GET https://conductscience.org/api/papers/v1/39348357/references?page=2